-
Lancet Oncol: Can cancer patients get the new crown vaccine?
Time of Update: 2021-05-08
Immunogenicity of BNT162b2 vaccineImmunogenicity of BNT162b2 vaccineSixteen healthy controls, 25 patients with solid tumors, and 6 patients with hematological tumors received the second dose of vaccine on day 21.
-
NEJM: ADC drug Sacituzumab govitecan first-line treatment of metastatic triple-negative breast cancer
Time of Update: 2021-05-08
Studies believe that for patients with metastatic triple-negative breast cancer who have previously been treated with paclitaxel, the ADC drug Sacituzumab-govitecan is superior to single-agent chemotherapy in terms of progression-free survival and overall survival, but adverse events of bone marrow suppression and diarrhea are more common.
-
Nature: A new era of cancer treatment!
Time of Update: 2021-05-08
For the first time, the research team has identified STM2457, a small molecule inhibitor of m6A methylase METTL3 that is active in the body, and further confirmed that the inhibitor can effectively inhibit the development of acute myeloid leukemia (AML).
-
Radiotherapy and Oncology: The influence of DNA repair and reactive oxygen levels on the radiation resistance of pancreatic cancer
Time of Update: 2021-05-08
The data from this study shows that repeated exposure to radiation increases the expression of genes involved in cell viability, leading to radioresistance.
Repeated exposure to radiation increases the expression of genes involved in cell viability, leading to radioresistance.
-
ESMO Open: Efficacy of avelumab combined with axitinib vs sunitinib for advanced sarcomatoid renal cell carcinoma
Time of Update: 2021-05-08
This article aims to evaluate the efficacy of avelumab combined with axitinib or sunitinib in untreated advanced sRCC patients with sunitinibThe JAVELIN Renal 101 study is a randomized, open-label, multi-center phase III clinical trial.
-
Lancet Oncol: The team of Professor Guo Xiang from Sun Yat-sen University Cancer Hospital confirmed through a phase 3 trial that the third-generation platinum drug lobaplatin can effectively treat locally advanced nasopharyngeal carcinoma!
Time of Update: 2021-05-08
Lobaplatin-based induction chemotherapy combined with concurrent radiotherapy is not inferior to cisplatin-based treatment for patients with locally advanced nasopharyngeal cancer, and the toxic side effects are smaller.
-
Br J Cancer: RNAscope technology to detect α-fetoprotein mRNA level is a new and highly specific marker for hepatocellular carcinoma
Time of Update: 2021-05-08
All in all, the results of the study revealed that the level of AFP mRNA detected by RNAscope is highly specific for hepatocellular malignancies, and it may be used as a new diagnostic biomarker for HCC.
-
2021 CSCO BC|Professor Yang Jin: Targeted Joint Strategy of Endocrine Therapy for Breast Cancer
Time of Update: 2021-05-08
The BYLieve study evaluated the efficacy of Alpelisib combined with endocrine therapy for CDK4/6 inhibitor + AI/fulvestrant treatment progress in HR+/HER2-, PIK3CA mutant breast cancer patients.
-
Br J Cancer: Geriatric intervention (CGA) can improve the chemotherapy prognosis of elderly patients with colorectal cancer
Time of Update: 2021-05-08
The Phase 3 clinical trial revealed that compared with standard care, geriatric intervention can increase the number of vulnerable elderly patients with CRC who complete adjuvant chemotherapy, and can improve the disease burden and quality of life of patients.
-
Autophagy: Wang Wuyang's team from Xuzhou Medical University found that targeting lysosomal ion channels can treat pancreatic cancer
Time of Update: 2021-05-08
In summary, these results indicate that the lysosomal cation channel MCOLN1 finely controls oncogenic autophagy in cancer by mediating zinc influx into the cytoplasm.
MCOLN1/TRPML1 finely controls oncogenic autophagy in cancer by mediating zinc influx.
-
Kangfang Bio-PD-1/CTLA-4 was approved to start a global phase 3 clinical trial for the treatment of cervical cancer
Time of Update: 2021-05-08
On April 28, Kangfang Bio-Bio announced that it has independently developed the world's first innovative tumor immunotherapy new drug Cadonilimab (PD-1/CTLA-4, R&D code: AK104) plus platinum-containing chemotherapy with or without bevacizumab It has been approved by the National Center for Drug Evaluation (CDE) to carry out a randomized, double-blind, placebo-controlled global phase III clinical study for the first-line treatment of persistent, recurrent or metastatic cervical cancer.
-
Nature: Liquid biopsy creates a new situation for precise cancer treatment
Time of Update: 2021-05-08
Cells that metastasize from a tumor to the blood can help doctors monitor the resistance of treatment drugsCells that metastasize from a tumor to the blood can help doctors monitor the resistance of treatment drugsLiquid biopsy can quickly find cancer biomarkers, which can help identify patients most likely to benefit from targeted therapy.
-
Brit J Cancer: Diagnosis of head and neck cancer based on artificial intelligence
Time of Update: 2021-05-08
This systematic review aims to review the use of artificial intelligence/machine learning (AI/ML) methods to automatically analyze images for diagnosis and evaluation of head and neck cancer (HNC) Research.
Original source:More and more studies have explored the role of AI/ML in the use of multiple imaging methods to assist HNC detection.
-
"Nature-Medical": "Subtraction" of CAR-T cells can have anti-tumor activity
Time of Update: 2021-05-08
Kymriah, which targets the CD19 antigen developed by the University of Pennsylvania School of Medicine in cooperation with Novartis, became the first to receive the US FDA The approved CAR-T therapy is used to treat children and young patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL, acute lymphoblastic leukemia).
-
Tobacco Control: This... research shows that people exposed to secondhand smoke have a 51% increased risk of oral cancer
Time of Update: 2021-05-07
Recently, international research teams from Portugal, the United Kingdom, Spain and the United States published a paper titled: Secondhand smoke exposure and oral cancer risk: a systematic review and meta-analysis in the Tobacco Control journal under BMJ.
-
For the first time, the clinical pharmacy community has carried out a special investigation in the field of tumor immunology
Time of Update: 2021-05-07
"We still have deficiencies in the field of original drug research and development. We hope to use this pharmacy research as an opportunity to drive closer collaboration between industry, academia, r
-
Br J Cancer: Body Mass Index (BMI) and Absolute Lymphocyte Count (ALC): Predictors of disease-free survival for breast cancer patients
Time of Update: 2021-05-07
do?w=%E5%BF%83%E8%A1%80%E7%AE%A1">heart blood vesselsThe study aims to assess the correlation between body mass index (BMI) and absolute lymphocyte count (ALC) in breast cancer patients and healthy women, and to determine the prognostic value of these factors in breast cancer.
-
The Health Commission responds to the shady treatment of tumors: the treatment principles are basically in line with the norms
Time of Update: 2021-05-07
Therefore, the approved drug indications or the medical plans written into the guidelines are likely to be For those who are lagging behind, we should give patients some super-indications or super-guideline treatments based on relatively sufficient clinical evidence to explore the diagnosis and treatment effects.
-
Jiahe Biotech released its 2020 annual results today
Time of Update: 2021-05-03
Clinical development – The key clinical registration trials of 3 products (GB224, GB221, GB242) have been completed, GB491 (Lerociclib) cyclin-dependent kinase 4/6 inhibitor for the first-line second-line bridging of HR+/HER2- advanced breast cancer patients The trial has been approved, and the first human trial (FIH) clinical trial application of the GB261 (CD20/CD3) bispecific antibody was submitted in Australia in March 2021
-
Take over charity assistance to Junshi Bio-Treplimumab National Medical Insurance Implementation
Time of Update: 2021-05-03
Recently, at the melanoma branch of the second CSCO-Junshi Bio-Tumor Immunity Summit Forum, the anti-PD-1 monoclonal antibody drug Teriplizumab Injection (Tuoyi®) "Yilu is accompanied by Bethune·Tuoyi" The charity donation project" successfully completed its mission and the melanoma indications were included in the national medical insurance catalogue to celebrate the landing ceremony.
